Analyst Price Targets — ICCM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 4, 2026 11:02 am | Scott Henry | Industrial Alliance Securities | $1.00 | $0.30 | TheFly | IceCure Medical initiated with a Buy at Alliance Global |
| August 15, 2025 10:18 am | Yi Chen | H.C. Wainwright | $2.00 | $0.86 | TheFly | IceCure Medical price target lowered to $2 from $2.50 at H.C. Wainwright |
| August 13, 2025 5:58 pm | Kemp Dolliver | Loop Capital Markets | $2.77 | $0.83 | StreetInsider | IceCure Medical Ltd. (ICCM) PT Lowered to $2.77 at Brookline Capital Markets |
| November 29, 2024 11:35 am | Yi Chen | H.C. Wainwright | $2.50 | $0.82 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on IceCure Medical Ltd. (ICCM) |
| May 19, 2022 10:06 am | Ben Haynor | Industrial Alliance Securities | $5.75 | $1.88 | TheFly | IceCure price target lowered to $5.75 from $9.50 at Alliance Global |
Latest News for ICCM
CAESAREA, Israel, July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the expansion of its United States ("U.S.") sales and marketing teams.
Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cancer cryoablation in 750 patients across Brazil, led by renowned breast surgeon Dr. Vanessa Sanvido, is underway Dr. Toulsie Ramtohul of Institut Curie, a ProSense™ user set to lead a 900-patient breast cancer cryoablation…
CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that on June 18, 2026, it received written notice from Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company has regained…
Published in the International Journal of Surgery, globally ranked in the top three among surgery journals , the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients IceCure preparing for the 2026 Japanese Breast Cancer Society meeting and planned regulatory submission for breast cancer in Japan by Terumo Corporation one of the…
CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor, for the purchase and sale of…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ICCM.
U.S. House Trading
No House trades found for ICCM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.